新医改下对国家基本药物指导价的药物经济学研究  

A Pharmacoeconomics Study of Guiding Price of National Basic Medicine in New Medical Reform

作　　者：黄自发[1] 季旭[1] 鲁翔[1] 

机构地区：[1]南京医科大学,南京210029

出　　处：《中国卫生经济》2010年第4期88-90,共3页Chinese Health Economics

摘　　要：目的:研究新医改下《国家基本药物目录》中基本药物指导价的制定。方法:在总结发现我国药品定价存在的问题和不足的基础上,对新医改下国家基本药物定价提供借鉴,并运用药物经济学原理确定国家基本药物的指导价。结果:运用药物经济学原理,从基本药物的真实成本和治疗效果出发,推导出基本药物的指导价公式。结论:在分析指导价的过程中,尚未考虑到医疗保险和国家补偿机制等因素对价格制定的影响以及患者的接受能力,指导价公式中的一些变量有较强的主观性,会对指导价产生一定的影响。Objective： As the the new medical reform is carried out, how to price the drugs in the list of essential medicines established. Methods： Through finding out the main problems and flaws in our country＇ s system of drugs＇ price, experience to how to fix the price of essential medicines can be given. And the theories of pharmacoeconomics are used, depending on the true costs and efficiency of the drugs. Results： Using the theories of Pharmacoeconomics, it is accurate to fix the price of essential medicines in China based on true costs and efficiency. Conclusion： During the process of analyzing guiding price in the paper, the impacts of pricing and accepting ability of patients from medical insurance and national compensation policy, etc, have not been taken into account. Some variable affects in the guiding price formula are of high objectivity, and would influence the guiding price.

关 键 词：新医改 国家基本药物 指导价 药物经济学 

分 类 号：R197.1[医药卫生—卫生事业管理]